SHORT REPORT

Narcolepsy associated with primary temporal lobe B-cells lymphoma in a HLA DR2 negative subject

M Onofri, L Curatola, F Ferracci, T Fulgente

Abstract
Narcolepsy and cataplexy began one year before treatment of a left mid-temporal primary B-cells lymphoma in a HLA DR2 negative man. Treatment with radio therapy and immunosuppression induced regression of the lymphoma and disappearance of narcolepsy and cataplexy.

(J Neurol Neurosurg Psychiatry 1992;55:852-853)

Symptomatic or secondary narcolepsy has been described in a number of diseases involving immune system or in CNS diseases such as Multiple Sclerosis head trauma, hypoxic ischaemia and tumours of the midbrain and diencephalon. A recent review, however, suggests that there is no unequivocal association of narcolepsy with other disorders and that some cases of so-called secondary narcolepsy-cataplexy may be examples of the association of separate disorders rather than causally related.

The major element prompting the redefinition of secondary narcolepsy was the finding of very high (99%) narcolepsy association with HLA DR2-DQw1 haplotypes in idiopathic and secondary cases: only a few white and black DR2 negative patients have been found.

We describe a patient affected by "unequivocal" (according to the criteria suggested by the Association of Sleep Disorders Centers) narcolepsy-cataplexy that was secondary to a CNS B-cells lymphoma.

Case report
The patient, a 30 year old white male, presented to us approximately one year after the onset of excessive daytime sleepiness (EDS) and uncontrollable daytime sleep attacks, lasting from 5 to 10 minutes, preceded by a dramatic abolition of voluntary movement. Such attacks interfered with his daily activities and on one occasion caused a minor driving accident.

In the preceding year his friends had noticed that he was often "dozing-off" and only the complaints of his fiancée forced him to visit our outpatient unit. He sometimes fell to the ground or, if sitting, felt his head dropping without loss of consciousness particularly during exciting or unpleasant situations. The patient was alert and orientated and the neurological examination was normal. Three sets of nocturnal EEGs revealed that "sleep" was spent as follows: 6% wake, 46% stage 1, 46% stage 2, 24% stage 3, 4 and 20% REM sleep. REM sleep latency was 3-5 minutes. MSLT was carried out in our sleep laboratory after a quiet night's sleep, by means of a polygraph recording EEG, EOG, EMG, ECG and nasal airflow. We recorded 5 scheduled nap periods starting 2 hours after awakening from

![Waveform graph](image-url)

Figure 1 - Polygraphic recording, performed one year before the appearance of CNS lymphoma, showing a sleep-onset REM (SOREM) Period. Note the sudden appearance from the stage of wake of a low voltage, fast EEG activity accompanied by Rapid Eye Movements, depression of muscular tone at the EMG and mild increase in heart and respiratory frequency (REM sleep). The monitoring of airflow by nasal thermistors shows no abnormality of breathing and excludes the presence of sleep apneas. Vertical calibration is 50 μV for EEG, 100 μV for eye movements, 300 μV for EMG and ECG.

Department of Neurology, Institute of Neurological and Behavioural Sciences, State University of Chieti, Chieti, Italy
M Onofri
L Curatola
F Ferracci
T Fulgente

Correspondence to:
Dr Onofri, Clinica Neurologica, Ospedale ex-Pediatrico, Via Martiri Lancianetti 6, 66100 Chieti, Italy

Narcolepsy associated with primary temporal lobe B-cells lymphoma in a HLA DR2 negative subject

1 Narcolepsy associated with B-cells lymphoma. CNS non-Hodgkin, high grade, B-cells, centroblastic Lymphoma. HIV antibody testing was negative again. Treatment with prednisone, radiotherapy (5000 cGy) and high dose methotrexate (1 gr/m²) was given. The intracranial hypertension disappeared in weeks. Brain CT performed six months after treatment showed only an area of residual lucency. Nocturnal EEG, and MSLT polygraphic recording, repeated three months, one year and two years after the last CT scan were normal. Narcolepsy and cataplexy were not clinically observed during second admission and in the following 30 months.

Discussion

After the critical reviews by Bonduelle and Degos and Parkes secondary narcolepsy is considered a rare or dubious clinical entity. To our knowledge there are no other reports describing narcolepsy in CNS lymphoma. The course of the disease had furthermore at least three peculiarities differentiating this patient from others reported in the literature: 1) Narcolepsy preceded by one year the appearance of the left mid temporal lobe lymphoma; 2) Narcolepsy disappeared when radiation therapy induced regression of the lymphoma; 3) the patient haplotype was DR2, DQw1 negative.

The typical history of primary brain lymphoma is known to be characterised by behavioural and personality changes or focal neurological signs that precede by several months symptoms due to increased intracranial pressure. We proposed that the unusual clinical picture we describe was due to a focal infiltration of lymphomatous cells in the basal forebrain, in particular the hypothalamus and the area of the third ventricle, which are involved in the regulation of sleep-wake cycle and REM sleep. Immunotherapy and/or radiotherapy may have suppressed the infiltrating lymphomatous cells.

7 Guilleminault C. HLA-DR2 and narcolepsy: not all narcoleptic-cataplectic patients are DR2. Human Immunol 1986;17:1-2.
Narcolepsy associated with primary temporal lobe B-cells lymphoma in a HLA DR2 negative subject.

M Onofrj, L Curatola, F Ferracci and T Fulgente

*J Neurol Neurosurg Psychiatry* 1992 55: 852-853
doi: 10.1136/jnnp.55.9.852

Updated information and services can be found at:
http://jnnp.bmj.com/content/55/9/852

These include:

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/